Escape from Cbl-mediated downregulation: A recurrent theme for oncogenic deregulation of receptor tyrosine kinases

Cancer Cell

Volumn 3, Issue 6, 2003, Pages 519-523

  Peschard, Pascal ^a   Park, Morag ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; COLONY STIMULATING FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; LYSOZYME; ONCOPROTEIN; POLYUBIQUITIN; PROTEASOME; PROTEIN; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BINDING SITE; CARCINOGENESIS; CATALYSIS; CELL SURFACE; CHROMOSOME TRANSLOCATION; DEREGULATION; DIMERIZATION; DOWN REGULATION; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME DEGRADATION; ENZYME LOCALIZATION; ENZYME REGULATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC CODE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OLIGOMERIZATION; ONCOGENE NEU; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SHORT SURVEY;

EID: 0038386452     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00136-3     Document Type: Review

References (33)

1. Bao J., Gur G., Yarden Y. Src promotes destruction of c-Cbl. implications for oncogenic synergy between Src and growth factor receptors Proc. Natl. Acad. Sci. USA. 100:2003;2438-2443.
2. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature. 411:2001;355-365.
3. Chan P.M., Ilangumaran S., La Rose J., Chakrabartty A., Rottapel R. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol. Cell. Biol. 23:2003;3067-3078.
4. Charest A., Kheifets V., Park J., Lane K., McMahon K., Nutt C.L., Housman D. Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc. Natl. Acad. Sci. USA. 100:2003;916-921.
5. Choi O.R., Trainor C., Graf T., Beug H., Engel J.D. A single amino acid substitution in v-erbB confers a thermolabile phenotype to ts167 avian erythroblastosis virus-transformed erythroid cells. Mol. Cell. Biol. 6:1986;1751-1759.
6. Clague M.J. Membrane transport. a coat for ubiquitin Curr. Biol. 12:2002;R529-R531.
7. Courbard J.R., Fiore F., Adelaide J., Borg J.P., Birnbaum D., Ollendorff V. Interaction between two ubiquitin-protein isopeptide ligases of different classes, CBLC and AIP4/ITCH. J. Biol. Chem. 277:2002;45267-45275.
8. de Melker A.A., van der Horst G., Calafat J., Jansen H., Borst J. c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route. J. Cell Sci. 114:2001;2167-2178.
9. Frederick L., Wang X.Y., Eley G., James C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60:2000;1383-1387.
10. Haglund K., Sigismund S., Polo S., Szymkiewicz I., Di Fiore P.P., Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat. Cell Biol. 5:2003;461-466.
11. Herbst R., Munemitsu S., Ullrich A. Oncogenic activation of v-kit involves deletion of a putative tyrosine-substrate interaction site. Oncogene. 10:1995;369-379.
12. Katzmann D.J., Odorizzi G., Emr S.D. Receptor downregulation and multivesicular-body sorting. Nat. Rev. Mol. Cell Biol. 3:2002;893-905.
13. Klapper L.N., Waterman H., Sela M., Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60:2000;3384-3388.
14. Lamorte L., Park M. The receptor tyrosine kinases. role in cancer progression Surg. Oncol. Clin. N. Am. 10:2001;271-288.
15. Lee P.S., Wang Y., Dominguez M.G., Yeung Y.G., Murphy M.A., Bowtell D.D., Stanley E.R. The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. EMBO J. 18:1999;3616-3628.
16. Lenferink A.E., Pinkas-Kramarski R., van de Poll M.L., van Vugt M.J., Klapper L.N., Tzahar E., Waterman H., Sela M., van Zoelen E.J., Yarden Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 17:1998;3385-3397.
17. Levkowitz G., Waterman H., Ettenberg S.A., Katz M., Tsygankov A.Y., Alroy I., Lavi S., Iwai K., Reiss Y., Ciechanover A.et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell. 4:1999;1029-1040.
18. Mancini A., Koch A., Wilms R., Tamura T. c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms. J. Biol. Chem. 277:2002;14635-14640.
19. Mosesson Y., Shtiegman K., Katz M., Zwang Y., Vereb G., Szollosi J., Yarden Y. Endocytsosis of receptor tyrosine kinases is driven by mono-, not poly-ubiquitylation. J. Biol. Chem. in press:2003.
20. Muthuswamy S.K., Gilman M., Brugge J.S. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol. Cell. Biol. 19:1999;6845-6857.
21. Peschard P., Fournier T.M., Lamorte L., Naujokas M.A., Band H., Langdon W.Y., Park M. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell. 8:2001;995-1004.
22. Petrelli A., Gilestro G.F., Lanzardo S., Comoglio P.M., Migone N., Giordano S. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature. 416:2002;187-190.
23. Ridge S.A., Worwood M., Oscier D., Jacobs A., Padua R.A. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc. Natl. Acad. Sci. USA. 87:1990;1377-1380.
24. Roussel M.F., Downing J.R., Rettenmier C.W., Sherr C.J. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell. 55:1988;979-988.
25. Schmidt M.H., Furnari F.B., Cavenee W.K., Bogler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc. Natl. Acad. Sci. USA. 100:2003;6505-6510.
26. Shtiegman K., Yarden Y. The role of ubiquitylation in signaling by growth factors. implications to cancer Semin. Cancer Biol. 13:2003;29-40.
27. Soubeyran P., Kowanetz K., Szymkiewicz I., Langdon W.Y., Dikic I. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature. 416:2002;183-187.
28. Thien C.B., Langdon W.Y. Cbl. many adaptations to regulate protein tyrosine kinases Nat. Rev. Mol. Cell Biol. 2:2001;294-307.
29. Waterman H., Katz M., Rubin C., Shtiegman K., Lavi S., Elson A., Jovin T., Yarden Y. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J. 21:2002;303-313.
30. Wilhelmsen K., Burkhalter S., van der Geer P. C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel phosphorylation site in the receptor's carboxy-terminus. Oncogene. 21:2002;1079-1089.
31. Wollberg P., Lennartsson J., Gottfridsson E., Yoshimura A., Ronnstrand L. The adapter protein APS associates with the multifunctional docking sites Tyr568 and Tyr936 in c-Kit. Biochem. J. 370:2003;1033-1038.
32. Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S., Sasaki A., Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A. APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis. Oncogene. 18:1999;759-767.
33. Yokouchi M., Kondo T., Sanjay A., Houghton A., Yoshimura A., Komiya S., Zhang H., Baron R. Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins. J. Biol. Chem. 276:2001;35185-35193.